Approvals and designations made by the U.S. Food and Drug Administration for the week ended June 15.
Approvals
* Roche Holding AG's Avastin-chemotherapy combination, for women with advanced ovarian cancer who had undergone surgery. Avastin is now approved in the U.S. for 10 uses across six types of cancer.
* Merck & Co. Inc.'s Keytruda, for primary mediastinal large B-cell lymphoma, as well as cervical cancer. Keytruda is already approved to treat multiple types of cancers.
* Medtronic PLC's IN.PACT Admiral balloons, to treat 200-millimeter and 250-millimeter lesions in patients with peripheral artery disease. The device's 360 millimeter version was approved in April.
* Mylan NV and Dr. Reddy's Laboratories Ltd.'s generic versions of Suboxone film, Indivior PLC's treatment for opioid use disorder.
* LivaNova PLC's Memo 4D, a semi-rigid mitral annuloplasty ring to treat mitral regurgitation.
* Cutera Inc.'s truSculpt 3D, a nonsurgical body sculpting system, for lipolysis. The device is already approved to reduce fat without surgery.
* Wright Medical Group NV's Augment injectable bone graft, for foot and ankle procedures. Wright Medical expects to launch the product within the next four to six weeks.
* Agilent Technologies Inc.'s Dako PD-L1 IHC 22C3 pharmDx, an in vitro diagnostic test to identify patients with non-small cell lung cancer or stomach cancer who would benefit from anti-PD-1 immunotherapy.
 |
| FDA headquarters in Silver Spring, Md. |
| Source: Associated Press |
Complete response letters
* ScPharmaceuticals Inc.'s Furoscix, which was meant to treat edema in people with heart failure. The FDA said ScPharmaceuticals needs to consider device modifications and conduct additional research.
Priority review
* Merck & Co.'s Gardasil 9, a human papillomavirus vaccine against certain cancers and diseases in men and women ages 27 to 45. The application's target action date is Oct. 6.
Fast track
* Regenxbio Inc.'s RGX-111, for mucopolysaccharidosis type I.
* Nordic Nanovector ASA's Betalutin, for certain patients with follicular lymphoma.
Other designations
* Regenerative medicine advanced therapy, for Nightstar Therapeutics Ltd.'s NSR-REP1, to treat choroideremia.
* Rare pediatric disease, for Albireo Pharma Inc.'s A4250, to treat progressive familial intrahepatic cholestasis. The FDA previously granted A4250 orphan drug status.